title: [Autologous transplantation of recombinant interleukine-2 activated bone marrow for acute promyelocytic leukemia].
abstract: OBJECTIVE
  To explore the benefit of autologous transplantation of interleukine-2 activated bone marrow (ABM) in acute promyelocytic leukemia (APL) as consolidation therapy.
  
  
  METHODS
  31 patients with APL, 27 in first complete remission (CR1), 3 in CR2, and 1 in partial remission (PR) after the second relapse, were treated with autologous transplantation of ABM. The conditioning regimens included MACC protocol (Melphalan, Ara-C, CTX, and CCNU) in 26 patients and TBI + CY protocol in 5 patients. The PML/RARa fusion gene was measured by fluorescence in situ hybridization. Kaplan-Meier survival analysis model was used to estimate the disease-free survival (DFS) rate at 5 years post-transplantation and COX regression model was used to analyze the DFS-influencing factors, including sex, PML/RARa positive state, pre-transplantation state (CR1, CR2, or PR), white blood cell (WBC) count, and platelet (PBC) count.
  
  
  RESULTS
  The 27 patients in CR1 had a DFS time of 3 to 113 months (with a mean DFS time of 46 months), and a 5-year DFS rate of 100%; none of them suffered a relapse after transplantation. One of the 3 patients in CR2 relapsed in 19 months after the transplantation and the other two patients had been in DFS state for 7 and 33 months respectively. The patient in PR obtained CR and relapsed 8 months after the transplantation. All the patients showed reconstitution of hematopoiesis. None of the patients died of transplantation-related complication. Multivariate analysis showed that long-term survival was correlated with the pre-transplantation statues and not with sex, positivity of PML/RARa, and WBC and PBC counts.
  
  
  CONCLUSIONS
  Autologous transplantation of ABM reduces the relapse and increases the long-term survival in the patients with APL in CR, especially in CR1.
authors.affiliation: Department of Hematology, Nanfang Hospital, First Military Medical University, Guangzhou 510515, China.
authors.forename: Qi-fa
authors.initials: QF
authors.lastname: Liu
authors.forename: Jing
authors.initials: J
authors.lastname: Sun
authors.forename: Yu
authors.initials: Y
authors.lastname: Zhang
authors.forename: Xiao-li
authors.initials: XL
authors.lastname: Liu
authors.forename: Bing
authors.initials: B
authors.lastname: Xu
authors.forename: Dan
authors.initials: D
authors.lastname: Xu
authors.forename: Ru
authors.initials: R
authors.lastname: Feng
authors.forename: Fan-yi
authors.initials: FY
authors.lastname: Meng
authors.forename: Lan-lin
authors.initials: LL
authors.lastname: Song
authors.forename: Shu-yun
authors.initials: SY
authors.lastname: Zhou
mesh_terms: D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation; D002648:Child; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000494:pharmacology*; D015473:Leukemia, Promyelocytic, Acute; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000235:genetics; D015514:Oncogene Proteins, Fusion / Q000235:genetics; D011994:Recombinant Proteins / Q000494:pharmacology; D012008:Recurrence; D014182:Transplantation, Autologous
chemical_list: D007376:Interleukin-2; D009363:Neoplasm Proteins; D015514:Oncogene Proteins, Fusion; D011994:Recombinant Proteins; C093476:promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein